TWO · 7427.TWO
Great Novel Therapeutics Biotech & Medicals
NT$64.00+NT$0.90 (+1.43%)
Great Novel Therapeutics Biotech & Medicals’s quoted price sits in the upper half of its reported 52-week range, 22.71% below the high.
Loading market information…
TWO · 4724.TWO · TWD
Stock price
Quote as of Oct 30, 2026, 06:41 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Meribank Biotech Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 53.93% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Meribank Biotech Co., Ltd, established in 2013 and headquartered in Taipei City, Taiwan, is a company dedicated to the cultivation, advancement, and banking of mesenchymal stem cells. The firm specializes in the preservation of various cell types, including mesenchymal stem cells sourced from the placenta and umbilical cord, hematopoietic stem cells from cord blood, and diverse immune cells. Additionally, Meribank is involved in developing advanced cellular cryopreservation protocols and provides postpartum nursing services.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$64.00+NT$0.90 (+1.43%)
Great Novel Therapeutics Biotech & Medicals’s quoted price sits in the upper half of its reported 52-week range, 22.71% below the high.
NT$32.30-NT$1.10 (-3.29%)
Chunghwa Chemical Synthesis & Biotech Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.82% below the high.
NT$29.45NT$0.00 (0.0%)
Genomics BioSci & Tech. Co.,Ltd.’s quoted price sits in the upper half of its reported 52-week range, 20.08% below the high.
NT$9.42-NT$0.25 (-2.59%)
Sunny Pharmtech Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.54% below the high.
NT$23.00-NT$1.05 (-4.37%)
Advagene Biopharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.38% below the high.
NT$16.90NT$0.00 (0.0%)
GenMont Biotech Incorporation’s quoted price sits in the lower half of its reported 52-week range, 14.43% below the high.
NT$18.70-NT$0.15 (-0.8%)
NaviFUS Corp.’s quoted price sits in the lower half of its reported 52-week range, 30.87% below the high.
NT$20.00-NT$0.50 (-2.44%)
Abnova (Taiwan) Corporation’s quoted price sits in the lower half of its reported 52-week range, 31.39% below the high.
